Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

MedWellAI (MWAI) EBITDA Margin (2016 - 2025)

MedWellAI (MWAI) has disclosed EBITDA Margin for 11 consecutive years, with 27.09% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 18616.0% to 27.09% in Q4 2025 year-over-year; TTM through Dec 2025 was 29.74%, a 11950.0% increase, with the full-year FY2025 number at 128.07%, changed N/A from a year prior.
  • EBITDA Margin was 27.09% for Q4 2025 at MedWellAI, up from 330.64% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1331.92% in Q2 2021 to a low of 51062.02% in Q3 2024.
  • A 5-year average of 2755.73% and a median of 113.0% in 2022 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: crashed -5020685bps in 2024, then skyrocketed 5073138bps in 2025.
  • MedWellAI's EBITDA Margin stood at 13.03% in 2021, then plummeted by -1166bps to 164.91% in 2022, then surged by 88bps to 19.42% in 2023, then plummeted by -998bps to 213.25% in 2024, then surged by 87bps to 27.09% in 2025.
  • Per Business Quant, the three most recent readings for MWAI's EBITDA Margin are 27.09% (Q4 2025), 330.64% (Q3 2025), and 1132.91% (Q2 2025).